Research programme: CID based cellular immunotherapies - Bellicum Pharmaceuticals

Drug Profile

Research programme: CID based cellular immunotherapies - Bellicum Pharmaceuticals

Alternative Names: BPX 401; BPX 601; BPZ-2003; CaspaCIDe® T Cell immunotherapies - Bellicum Pharmaceuticals; Chemical Induction of Dimerization enabled cellular immunotherapies - Bellicum Pharmaceuticals; CIDeCar#1; DeCIDe® based immunotherapies - Bellicum pharmaceuticals; GoCAR-T based immunotherapies - Bellicum Pharmaceuticals

Latest Information Update: 04 Nov 2016

Price : $50

At a glance

  • Originator Bellicum Pharmaceuticals
  • Class Cancer vaccines; CAR-T cell therapies; Cell therapies; Dendritic cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants; T lymphocyte replacements; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies; Pancreatic cancer
  • No development reported Solid tumours

Most Recent Events

  • 01 Nov 2016 Bellicum and Ospedale Pediatrico Bambino Gesù collaborate on the development of CAR T-cell therapies and TCR cell therapies
  • 01 Nov 2016 Bellicum Pharmaceuticals plans a phase I/II clinical trial for BPX 401 in Acute lymphoblastic leukaemia (In children, In infants)
  • 08 Aug 2016 US FDA approves IND application for BPX-601 in Pancreatic cancer (Inoperable/Unresectable)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top